Basilea Pharmaceutica AG (SWX: BSLN)
Health Care · Biotechnology · CH
CHF65.70
+0.31% today · +33.4% 1Y
Basilea Pharmaceutica AG (SWX: BSLN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $979.21M and employs 200 people.
Over the last twelve months the share price has gained 33.4%, trading between 44.70 and 70.50.
Tweenvest scores Basilea Pharmaceutica AG across four factors: quality 81/100, value 52/100, growth 81/100. Its strongest factor is quality.
BSLN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $979.21M
- Revenue (TTM)
- $306.21M
- P/E
- 16.33
- EPS
- 4.01
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- CHF70.50
- 52-week low
- CHF44.70
- Avg volume (3M)
- —
- Shares outstanding
- 12.42M
- Employees
- 200
- Next earnings
- —
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
- ISIN
- CH0011432447
- Founded
- 2000
- Listed since
- Mar 25, 2004
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Adlai Nortye Group Ltd.NasdaqGM: ANL | $1.01B | $14.30 | -8.45% |
| Cullinan Therapeutics, Inc.NasdaqGS: CGEM | $999.43M | $15.23 | -1.93% |
| Philogen S.p.A.BIT: PHIL | $991.45M | €21.70 | -1.36% |
| Jiangsu Aidea Pharmaceutical Group Co., Ltd.SHSE: 688488 | $989.43M | CN¥15.75 | -5.29% |
| Shanghai Haohai Biological Technology Co., Ltd.SEHK: 6826 | $943.26M | HK$16.11 | +0.25% |
| Kura Oncology, Inc.NasdaqGS: KURA | $942.98M | $10.36 | -2.26% |
| Ascletis Pharma Inc.SEHK: 1672 | $936.85M | HK$6.96 | -14.23% |
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $932.34M | ₩25,350.00 | -12.13% |
Figures last refreshed Oct 11, 2026.